Soluble Klotho levels in diabetic nephropathy: Relationship with arterial stiffness

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 15, 2016, Pages 3230-3237

  Inci, A ^a   Sari, F ^b   Olmaz, R ^a   Coban, M ^a   Dolu, S ^a   Sarikaya, M ^a   Ellidag, H Y ^c  

^a Division of Neonatology   (Turkey)

^b Faculty of Medicine   (Turkey)

^c ANTALYA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Arterial stiffness; Chronic kidney disease; Diabetic nephropathy; Fibroblast growth factor 23; Soluble Klotho

Indexed keywords

CALCIFEDIOL; CALCIUM ION; CREATININE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHORUS; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; CALCIUM;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MONITOR; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PULSE PRESSURE; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; MIDDLE AGED; BLOOD PRESSURE; BONE MINERAL; CHRONIC KIDNEY FAILURE; ESTIMATED GLOMERULAR FILTRATION RATE;

AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; VASCULAR STIFFNESS;

EID: 85017188774     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. SÜLEYMANLAR G, UTA C, ARINSOY T, ATE K, ALTUN B, ALTIPARMAK MR, ECDER T, YILMAZ ME, ÇAMSARI T, BA ÇI A, ODABAS AR, SERDENGEÇTIK. A population-based survey of chronic renal disease in Turkey-the CREDIT study. Nephrol Dial Transplant 2011; 26: 1862-1871.
2. BERNHEIM J, BENCHETRIT S. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant 2011; 26: 2433-2436.
3. WANG Y, SUN Z. Current understanding of Klotho. Ageing Res Rev 2009; 8: 43-51.
4. KOMABA H, FUKAGAWA M. The role of FGF23 in CKD-with or without Klotho. Nat Rev Nephrol 2012; 8: 484-490.
5. KITAGAWA M, SUGIYAMA H, MORINAGA H, INOUE T, TAKIUE K, OGAWA A, YAMANARI T, KIKUMOTO Y, UCHIDA HA, KITAMURA S, MAESHIMA Y, NAKAMURA K, ITO H, MAKINO H. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One 2013; 8: e56695.
6. ISAKOVA T, WAHL P, VARGAS GS, GUTIÉRREZ OM, SCIALLA J, XIE H, APPLEBY D, NESSEL L, BELLOVICH K, CHEN J, HAMM L, GADEGBEKU C, HORWITZ E, TOWNSEND RR, ANDERSON CA, LASH JP, HSU CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
7. EVENEPOEL P, MEIJERS B, VIAENE L, BAMMENS B, CLAES K, KUYPERS D, VANDERSCHUEREN D, VANRENTERGHEM Y: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 1268-1276.
8. YAMASHINA A, TOMIYAMA H, ARAI T, HIROSE K, KOJI Y, HIRAYAMA Y, YAMAMOTO Y, HORI S. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003; 26: 615-622.
9. KAWAMOTO R, KOHARA K, TABARA Y, MIKI T, OHTSUKA N, KUSUNOKI T, YORIMITSU N. An association between decreased estimated glomerular filtration rate and arterial stiffness. Intern Med 2008; 47: 593-598.
10. WANG MC, TSAI WC, CHEN JY, HUANG JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45: 494501.
11. CERNES R, ZIMLICHMAN R, SHARGORODSKY M. Arterial elasticity in cardiovascular disease: Focus on hypertension, metabolic syndrome and diabetes. Adv Cardiol 2008; 45: 65-81
12. STEHOUWER CD, HENRY RM, FERREIRA I. Arterial stiffness in diabetes and the metabolic syndrome: A pathway to cardiovascular disease. Diabetologia 2008; 51: 527-539.
13. YAMASHINA A, TOMIYAMA H, TAKEDA K, TSUDA H, ARAI T, HIROSE K, KOJI Y, HORI S, YAMAMOTO Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
14. TSUCHIKURA S, SHOJI T, KIMOTO E, SHINOHARA K, HATSUDA S, KOYAMA H, EMOTO M, NISHIZAWA Y. Brachialankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17: 658-665.
15. LIM K, LU TS, MOLOSTVOV G, LEE C, LAM FT, ZEHNDER D, HSIAO LL. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012; 125: 2243-2255.
16. SAITO Y, YAMAGISHI T, NAKAMURA T, OHYAMA Y, AIZAWA H, SUGA T, MATSUMURA Y, MASUDA H, KURABAYASHI M, KURO-O M, NABESHIMA Y, NAGAI R. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998; 248: 324-329.
17. KUSABA T, OKIGAKI M, MATUI A, MURAKAMI M, ISHIKAWA K, KIMURA T, SONOMURA K, ADACHI Y, SHIBUYA M, SHIRAYAMA T, TANDA S, HATTA T, SASAKI S, MORI Y, MATSUBARA H. Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci U S A 2010; 107: 19308-19313.
18. YILMAZ MI, SONMEZ A, SAGLAM M, YAMAN H, KILIC S, DEMIRKAYA E, EYILETEN T, CAGLAR K, OGUZ Y, VURAL A, YENICESU M, ZOCCALI C. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78: 679-685.
19. SUGIURA H, TSUCHIYA K, NITTA K. Circulating levels of soluble a-Klotho in patients with chronic kidney disease. Clin Exp Nephrol 2011; 15: 795-796.
20. DEVARAJ S, SYED B, CHIEN A, JIALAL I. Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease.Am J Clin Pathol 2012; 137: 479-485.
21. SHIMAMURA Y, HAMADA K, INOUE K, OGATA K, ISHIHARA M, KAGAWA T, INOUE M, FUJIMOTO S, IKEBE M, YUASA K, YAMANAKA S, SUGIURA T, TERADA Y. Serum levels of soluble secreted alpha-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 2012; 16: 722-729.
22. YOKOYAMA K, IMURA A, OHKIDO I, MARUYAMA Y, YAMAZAKI Y, HASEGAWA H, URAE J, SEKINO H, NABESHIMA Y, HOSOYA T. Serum soluble a-Klotho in hemodialysis patients. Clin Nephrol 2012; 77: 347-351.
23. AKIMOTO T, KIMURA T, WATANABE Y, ISHIKAWA N, IWAZU Y, SAITO O, MUTO S, YAGISAWA T, KUSANO E. The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplant Proc 2013; 45: 134-136.
24. PAVIK I, JAEGER P, EBNER L, WAGNER CA, PETZOLD K, SPICHTIG D, POSTER D, WÜTHRICH RP, RUSSMANN S, SERRA AL. Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013; 28: 352-359.
25. SEILER S, WEN M, ROTH HJ, FEHRENZ M, FLÜGGE F, HERATH E, WEIHRAUCH A, FLISER D, HEINE GH. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2013; 83: 121-128.
26. KACSO IM, BONDOR CI, KACSO G. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin Biochem 2012; 45: 1415-1420.
27. KURO-O M. Klotho in health and disease. Curr Opin Nephrol Hypertens 2012; 21: 362-368.
28. CHOI BH, KIM CG, LIM Y, LEE YH, SHIN SY. Transcriptional activation of the human Klotho gene by epidermal growth factor in HEK293 cells; role of Egr-1. Gene 2010; 450: 121-127.
29. BEN-DOV IZ, GALITZER H, LAVI-MOSHAYOFF V, GOETZ R, KURO-O M, MOHAMMADI M, SIRKIS R, NAVEH-MANY T, SILVER J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
30. HEIJBOER AC,BLANKENSTEIN MA, HOENDEROP J, DE BORST MH, VERVLOET MG. Laboratory aspects of circulating a-Klotho. Nephrol Dial Transplant 2013; 28: 2283-2287.
31. YAMAZAKI Y, IMURA A, URAKAWA I, SHIMADA T, MURAKAMI J, AONO Y, HASEGAWA H, YAMASHITA T, NAKATANI K, SAITO Y, OKAMOTO N, KURUMATANI N, NAMBA N, KITAOKA T, OZONO K, SAKAI T, HATAYA H, ICHIKAWA S, IMEL EA, ECONS MJ, NABESHIMA Y. Establishment of sandwich ELISA forsoluble alpha-Klotho measurement: age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 2010; 398: 513-518.
32. HU MC, SHI M, ZHANG J, QUIÑONES H, GRIFFITH C, KURO-O M, MOE OW. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-36.
33. GO AS, CHERTOW GM, FAN D, MCCULLOCH CE, HSU CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
34. SAFAR ME, LONDON GM, PLANTE GE. Arterial stiffness and kidney function. Hypertension 2004; 43: 163-168.
35. KUWAHARA N, SASAKI S, KOBARA M, NAKATA T, TATSUMI T, IRIE H, NARUMIYA H, HATTA T, TAKEDA K, MATSUBARA H, HUSHIKI S. HMG-CoA reductase inhibition improves anti-aging klotho protein expression and artriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol 2008; 123: 84-90.